Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)-Reference-Cited by-同舟云学术

Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)

Published:2012-11-02 Issue:2 Volume:207 Page:248-256
ISSN:1537-6613
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Barouch Dan H.,Liu Jinyan,Peter Lauren,Abbink Peter,Iampietro M. Justin,Cheung Ann,Alter Galit,Chung Amy,Dugast Anne-Sophie,Frahm Nicole,McElrath M. Juliana,Wenschuh Holger,Reimer Ulf,Seaman Michael S.,Pau Maria G.,Weijtens Mo,Goudsmit Jaap,Walsh Stephen R.,Dolin Raphael,Baden Lindsey R.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/207/2/248/16866602/jis671.pdf

Reference41 articles.

1. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection;Flynn;J Infect Dis,2005

2. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand;Pitisuttithum;J Infect Dis,2006

3. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial;Buchbinder;Lancet,2008

4. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand;Rerks-Ngarm;N Engl J Med,2009

5. Challenges in the development of an HIV-1 vaccine;Barouch;Nature,2008

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical trials and recent progress in HIV vaccine development;Functional & Integrative Genomics;2024-08-28

2. Peak transgene expression after intramuscular immunization of mice with adenovirus 26-based vector vaccines correlates with transgene-specific adaptive immune responses;PLOS ONE;2024-04-16

3. Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine;Journal of Virology;2023-11-30

4. Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF–Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study;The Journal of Infectious Diseases;2023-07-11

5. Factors, enablers and challenges for COVID-19 vaccine development;BMJ Global Health;2023-06